Merck, Schering-Plough tap DDB for new account

Published on .

Joint marketers Merck & Co. and Schering-Plough Corp. have tapped DDB Worldwide, New York, to handle the launch of a developmental cholesterol-lowering drug known by its generic name ezetimibe, executives close to the matter said. DDB outdueled Grey Worldwide, New York, to win the account, with billings that could approach $50 million. Also, Bristol-Myers Squibb has shifted its estimated $60 million Pravachol account to Robert A. Becker, New York, after a review, executives close to the matter said. Pravachol was housed at Bozell, New York.

Copyright January 2001, Crain Communications Inc.

In this article:
Most Popular